Taken together, our findings broaden the insight into the molecular mechanism of chemoresistance in NPC, and the USP10-ATMIN-LCK axis provides potential therapeutic targets for the management of NPC. The gene discussed is LCK; the disease is nasopharyngeal carcinoma.